Broad-based performance drives sales, profits and earnings growth:

• Total Q1 2024 sales £7.4 billion +10% and +13% ex COVID
• Vaccines sales +16%, +22% ex COVID. Shingrix £0.9 billion +18%, Arexvy £0.2 billion
• Specialty Medicines sales +17%, +19% ex COVID with HIV +14%
• General Medicines sales +1%. Trelegy £0.6 billion +33%
• Total operating profit and Total EPS for Q1 2024 reflected higher charges for CCL remeasurement, partly offset by strong Core growth
• Core operating profit +27% (with further positive impact of +8% ex COVID) and Core EPS +28% (with further positive impact of +9% ex COVID). This reflected strong sales and SG&A leverage, partly offset by increased investment in R&D and lower royalty income
• Cash generated from operations exceeded £1 billion with free cash flow of £0.3 billion

R&D delivery and targeted business development supports future growth:

• Strong pipeline progress with positive phase III read outs for gepotidacin in uncomplicated urogenital gonorrhoea, Cabenuva in HIV treatment, Jemperli in endometrial cancer, and Blenrep in multiple myeloma
• Innovative Vaccine portfolio further strengthened with regulatory submission acceptances for Arexvy for prevention of RSV in adults 50-59 (US), new meningococcal ABCWY vaccine candidate (US), and Shingrix for prevention of shingles in at-risk adults >18 (China)
• US FDA Fast Track designation received for bepirovirsen in chronic hepatitis B
• New positive data for CAB-ULA as ultra long-acting treatment for HIV supports progression and transition of HIV portfolio for long-term growth
• US FDA regulatory submission accepted for priority review for Jemperli to treat endometrial cancer in broader patient populations
• Acquisition of Aiolos Bio completed, expanding respiratory biologics pipeline with AIO-001, a potentially best-in-class long-acting TSLP monoclonal antibody for treatment of asthma

2024 guidance updated and dividends:

• Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%)
• Dividend declared of 15p for Q1 2024; 60p expected for Full Year 2024

Emma Walmsley, Chief Executive Officer, GSK:

"We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data read outs for 4 phase III medicines. These, together with other R&D achievements, mean we have strengthened prospects for growth in all of our key therapeutic areas this quarter: infectious diseases, HIV, respiratory/immunology and oncology. We expect this strong momentum to continue, and look forward to delivering another year of meaningful growth in sales and earnings in 2024.”